Kymera Therapeutics, Inc.
Clinical trials sponsored by Kymera Therapeutics, Inc., explained in plain language.
A clinical-stage biotech developing targeted protein degradation drugs.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Oral asthma drug KT-621 tested for Long-Term safety
Disease control Recruiting nowThis study looks at the long-term safety and effectiveness of an oral drug called KT-621 in people with asthma. Participants have already completed a previous KT-621 asthma study. The goal is to see how well the drug works over time and if any side effects appear with longer use.
Phase: PHASE2 • Sponsor: Kymera Therapeutics, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New asthma pill shows promise in Mid-Stage trial
Disease control Recruiting nowThis study tests an oral drug called KT-621 in 264 adults with moderate to severe eosinophilic asthma that is not well controlled by current treatments. Participants will take either KT-621 or a placebo daily for several weeks. Researchers will measure changes in lung function an…
Phase: PHASE2 • Sponsor: Kymera Therapeutics, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug KT-579 enters first human tests – no disease, just safety check
Knowledge-focused Recruiting nowThis early-stage study is testing a new oral drug, KT-579, in 96 healthy adults to see if it is safe and how the body handles it. Participants receive either the drug or a placebo. The goal is to gather safety data, not to treat any disease.
Phase: PHASE1 • Sponsor: Kymera Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC